Mandate

Vinge has advised Pandox in connection with a directed share issue of SEK 2 billion

September 18, 2024

Vinge has advised the hotel property owner Pandox Aktiebolag (publ) in connection with a directed share issue through which the company raises proceeds of approximately SEK 2 billion before transaction costs.

The company intends to use the proceeds to maintain the company’s strong financial position following hotel acquisitions in London and Edinburgh and to increase the company’s financial flexibility for additional property acquisitions and investments in existing properties. The Pandox share is listed on Nasdaq Stockholm.

Vinge’s team consisted of Jesper Schönbeck, Joel Magnusson, Adrian Filipovic and Maximilian Bengtsson.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026